|
Volumn 31, Issue 4, 2010, Pages 145-147
|
Role of immunohistochemistry in lymphoma
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BIOLOGICAL MARKER;
CD2 ANTIGEN;
CD20 ANTIGEN;
CD34 ANTIGEN;
CD5 ANTIGEN;
CD79A ANTIGEN;
CD99 ANTIGEN;
COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;
CYCLIN D1;
CYCLOPHOSPHAMIDE;
DACETUZUMAB;
DOXORUBICIN;
EPRATUZUMAB;
GALIXIMAB;
INTERFERON REGULATORY FACTOR 4;
LEUKOSIALIN;
MONOCLONAL ANTIBODY;
MYC PROTEIN;
PREDNISONE;
PROTEIN BCL 2;
PROTEIN BCL 6;
RITUXIMAB;
SGN 30;
TRANSCRIPTION FACTOR PAX5;
VINCRISTINE;
ARTICLE;
B CELL LYMPHOMA;
CHRONIC LYMPHATIC LEUKEMIA;
CLASSICAL HODGKIN LYMPHOMA;
FOLLICULAR LYMPHOMA;
GERMINAL CENTER;
HODGKIN DISEASE;
HUMAN;
IMMUNOHISTOCHEMISTRY;
IMMUNOPHENOTYPING;
LARGE CELL LYMPHOMA;
LYMPHOMA;
MANTLE CELL LYMPHOMA;
MARGINAL ZONE LYMPHOMA;
MORPHOLOGY;
NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA;
NONHODGKIN LYMPHOMA;
NONHUMAN;
PATHOGENESIS;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHENOTYPE;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
RECURRENT CANCER;
T CELL LYMPHOMA;
TREATMENT OUTCOME;
|
EID: 79551691235
PISSN: 09715851
EISSN: 09752129
Source Type: Journal
DOI: 10.4103/0971-5851.76201 Document Type: Article |
Times cited : (21)
|
References (5)
|